Lund, Sweden, 12 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq in New York, from 17:00-17:30 EDT, on Tuesday 19 May, 2026. Read more…
Lund, Sweden, 8 April, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January – March 2026 on 23 April, 2026. Interested parties may join the Company’s quarterly conference call on the same date at 14:00 CEST / 8:00 AM EDT. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan […]
— Financing brings total funds committed to date to >$95 million — Proceeds support the STARLYS clinical trial evaluating targeted LTBR agonist MST-0312 in solid tumors, together with platform and pipeline activities in inflammatory diseases — Expands the leadership team with exceptional development executives to propel the clinical advancement of the pipeline Cambridge, UK, March […]
Lund, Sweden, 13 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will be presenting at Redeye Theme Event: Commercialization in Life Science in Stockholm, at 10:15 AM CET on Friday 20 March, 2026. Hansa Biopharma VP Global Corporate Affairs Kerstin Falck will also be attending […]
Lund, Sweden, 9 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be participating in a panel discussion titled “The Path to Public: Mastering Your Exit Strategy” at LSX Investival Showcase USA in Miami, at 15:15 PM EDT on Tuesday 10 March, 2026. Hansa Biopharma COO […]
